Missed the webinar? No problem! 🎥 Watch the playback of "Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab™ and High-Throughput Single B Cell Screening AbDrop™". 🔗 https://lnkd.in/gBtAEYWS 💡 Ready to elevate your antibody drug discovery journey? Share your thoughts and explore further insights in the comments below! #Webinar #AntibodyDrugDiscovery #HUGOAb #AbDrop #Biotech #Research #Cyagen #antibody #scienceandcommunication
Cyagen’s Post
More Relevant Posts
-
The Antibody and Engineering Therapeutics Europe conference is next week! Join Stefanie Kall, Ph.D. for a talk on how to de-risk your antibody development workflows using high-resolution thermal and colloidal stability data on your antibody constructs. Stop by booth #18 to chat more about antibody stability characterization. #AntibodyEng
To view or add a comment, sign in
-
-
Join us Feb 28 the upcoming Webinar to learn how Beacon technology enables raipd discovery of monicolonal antibodies across different species and B cell sources!!!
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0
To view or add a comment, sign in
-
Webinar tomorrow!! Still using hybridoma? Sequencing and re-expressing thousands of useless hits? You don’t need to! Register below and find out why Beacon is both the present AND future gold standard in antibody discovery! #bruker #beacon #antibodydiscovery #singlecellanalysis #nextgenai
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery | Bruker Cellular Analysis
To view or add a comment, sign in
-
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery | Bruker Cellular Analysis
To view or add a comment, sign in
-
Membrane proteins are essential for cell signaling, catalysis, and ion channels, often becoming crucial in disease states and targets for drug development and anticancer therapies. Their intrinsic hydrophobicity, complex topologies, and dynamic conformations pose challenges in using them as antigens for antibody discovery. Innovative strategies are necessary to enhance antibody discovery success against membrane targets. Explore our blog on using membrane proteins as antigens for antibody discovery campaigns: https://hubs.li/Q02sfltq0 #TransmembraneProteins #MembraneProteins #AntibodyDiscovery #ProteinPurification
To view or add a comment, sign in
-
-
A beacon of precision in the dynamic world of biologics, STAT3 Monoclonal Antibody has been placed. Our STAT3 Monoclonal Antibody stands as a testament to innovation, designed to revolutionize therapeutic approaches by precisely targeting key signaling pathways. Elevate your research and therapeutic strategies with the unparalleled specificity and efficacy of our major discovery antibody. Excited to backpack on the transformative journey with GeNext Genomics, where breakthroughs become a reality. Explore the limitless potential of the STAT3 Monoclonal Antibody and witness the future of precision medicine unfold. . To Read More - https://lnkd.in/gXAd9Ace #GeNextGenomics #HighQualityBiologics #MonoclonalAntibody #STAT3Antibody #PrecisionMedicine
To view or add a comment, sign in
-
-
Get a sneak peek at the latest #validationstudies from the Generative Biologics Platform here 👇
Get a sneak peek at the validation studies This week, we want to sneak a peek at our #validationstudies of the Generative Biologics platform. During the development of our models, we assessed their ability to optimize an #antibody based on the 3D complex. We conducted an in silico study using Thymic Stromal Lymphopoietin (TSLP) and the anti-TSLP antibody Tezepelumab (PDB: 5j13). Here’s what we’ve accomplished: Novel CDRH3 Sequences: We masked the CDRH3 region of the antibody in the initial complex. Using our in-house Ab-specific protein language model (PLM), we generated 1,000 novel CDRH3 sequences. In Silico Analysis: -We folded the optimized antibody sequences and aligned them with the real binder. -Through RMSD filtering, which compares new structures to the real binder, we identified 21 promising hits with similar geometry. -Our calculations showed that 7 of these antibodies exhibited binding energy profiles comparable to or better than the initial binder. This brief study demonstrates how models used in #GenerativeBiologics can accelerate your research. More detailed platform validation, including in vitro testing results, will be available in our upcoming article. Stay tuned! For now, stay up to date by visiting: https://bit.ly/4e1wHXD
To view or add a comment, sign in
-
-
Get a sneak peek at the validation studies This week, we want to sneak a peek at our #validationstudies of the Generative Biologics platform. During the development of our models, we assessed their ability to optimize an #antibody based on the 3D complex. We conducted an in silico study using Thymic Stromal Lymphopoietin (TSLP) and the anti-TSLP antibody Tezepelumab (PDB: 5j13). Here’s what we’ve accomplished: Novel CDRH3 Sequences: We masked the CDRH3 region of the antibody in the initial complex. Using our in-house Ab-specific protein language model (PLM), we generated 1,000 novel CDRH3 sequences. In Silico Analysis: -We folded the optimized antibody sequences and aligned them with the real binder. -Through RMSD filtering, which compares new structures to the real binder, we identified 21 promising hits with similar geometry. -Our calculations showed that 7 of these antibodies exhibited binding energy profiles comparable to or better than the initial binder. This brief study demonstrates how models used in #GenerativeBiologics can accelerate your research. More detailed platform validation, including in vitro testing results, will be available in our upcoming article. Stay tuned! For now, stay up to date by visiting: https://bit.ly/4e1wHXD
To view or add a comment, sign in
-
-
🧬 Antibody discovery for tough targets like GPCRs is no easy task! 💪 Increase your chances of success with Nanovial Multicell Assays. Learn more in our upcoming webinar! 📌 Register here: https://lnkd.in/gmHR5ERt #AntibodyDiscovery #GPCRs #Antibodies #Nanovials #MulticellAssays
To view or add a comment, sign in
-
Preclinical data on Xencor's investigational anti #TL1A antibody, XmAb942, were presented at #UEGW2024 by our Vice President of Development Sciences, James Ernst. Dr. Ernst fielded important audience questions about our potential best-in-class molecule, our clinically validated Xtend™ half-life improvement, the translation of #pharmacokinetics for half-life extended molecules from preclinical models to humans, and the importance of thermostability in manufacturing. XmAb942 is in development for patients with inflammatory bowel disease #IBD. We have guided to the first subject entering a Phase 1 clinical study in the fourth quarter of 2024. Our press release and important disclosures on forward-looking statements are available here: https://lnkd.in/gWZ85u9s And our poster is available here: https://xn.cr/?c=2410a
To view or add a comment, sign in
-